|
| NOVEMBER
3, 2026 |
| Regional
intelligence on rugs, Diagnostics, Devices
& Digital Health |
|
|
|
* may need subscription to view |
|
BIG4BIO
CEO WEEKLY Q&A:
Lewis H. Bender, Founder & CEO,
Intensity Therapeutics |
| In
this Q&A, Bender discusses the insight
behind Intensity's approach, what sets its
delivery platform apart, lessons he's
learned leading a biotech company through
an IPO and late-stage trials, and changes
needed to get more effective, less toxic
treatments to patients faster. More |
|
|
|
Our
Newest Location: Mispro San
Diego!
Reserve your space today in
our Sorrento Mesa
Contract Vivarium |
|
Learn More
→ |
|
|
- Boston
Scientific Corporation: SIMPLAAFY Study of the
WATCHMAN FLX Pro Left Atrial Appendage Closure
Device Meets primary Endpoints More
- Elucid:
ELUCIDATE Study Demonstrates 93 Percent
Accuracy With Strong Performance in the "Gray
Zone" for FDA-cleared FFR-IQ More
- Illumina:
Selected to Help Bring Precision Medicine Into
Everyday Healthcare in Singapore More
- VivoSim
Labs and Chemveda Life Sciences: Join Forces
to Put AI-Designed Drug Candidates to the
Human Test More
|
|
 |
|
|
Investment Banking Advisory to the
Life Science Industry |
|
Learn More
→ |
|
|
- Biocentury: Pharma's U.S. Contributions
Favor Incumbents More*
- BioXconomy: Globalization Reimagined in
Biopharma More
- More on Setara Launching With $90M to Chase
Rare Disease Genetics at Scale More
- Neurocrine Biosciences: Third-Quarter 2026
Financial Results More
- StockWatch: Gene Editing Shares Jump on
ESGCT Data, FDA Draft Guidance More
- Travere Therapeutics: Third Quarter 2026
Financial Results More
- UCSD: New $15M Department of Energy
Genesis Award Will Use AI to Decode the
Shape of RNA More
- Zentalis Pharmaceuticals: Inducement Grants
Under Nasdaq Listing Rule 5635(c)(4) More
|
|
- Big4Bio CEO Weekly Q&A: Lewis H.
Bender, Founder & CEO, Intensity
Therapeutics More
- Biotech & Pharma Updates | November 2,
2026 More
- Subscribe to LifeSci Startup for
Updates on US Startups More
- UCSD: RNA-Protein Interactions Reveal New
Coronavirus Drug Targets More
|
|
 |
| Slone
Partners Places Farhad Ghavami as
Chief Executive Officer at
SeqCenter |
|
Learn More
→ |
|
|
- CollectiveMinds: The Boardroom Is
Changing. Is Your Experience Visible? More
- Crown Bioscience: Appoints Guy Sheets as
Senior Vice President, Commercial More
- ICYMI: Chutes & Ladders—Lilly Unifies
Global Markets As 36-Year Vet Patrik Jonsson
Retires More
- OPPORTUNITY: Director of Compliance, Remote
More
- OPPORTUNITY: Head of Market Development
& Strategy, California More
- OPPORTUNITY: Senior Vice President,
Regulatory Affairs & Quality Assurance,
Boston More
- Slone Partners: Doing More With Less
- Building the Right Nonprofit Leadership
Team in a Resource-Constrained Environment More
- Slone Partners: Leading Through AI - The New
Playbook for HealthTech Executives More
- U.S. Bioscience Jobs Up 7% From 2021 to
2025: Report More
|
|
 |
Events
|
Note:
Events may be in any Big4Bio region or
virtual |
|
- Aggression in Mice: Bridging Evidence,
Best Practices, and Scientific Rigor Nov
4
- Scaling Academic Research Programs
Through Strategic Colony Management
Partnerships Nov
11
- 23rd Annual Pantheon Awards Nov
12
- 2026 LSPA Patient Summit Nov
12
- Patient Pathways (Use code 26B4B10
for 10% off) Nov
17-20
- Pricing & Contracting WEST (Use
code 26B4B10 for 10% off) Dec
7-8
- Trade and Channel Strategies (Use
code 26B4B10 for 10% off) Dec
8-10
- Advancing Drug Development Forum Dec
10
|
SEE FULL
EVENT SCHEDULE AT THE BIOCALENDAR
|
|
DISCOVER COMPANIES |
|
Big4Bio: San Diego Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
|
|
|
|
|
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:San
Diego, all rights reserved
2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|